Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.
Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of ...
The FDA granted breakthrough therapy designation to a Vertex Pharmaceuticals kidney disease drug.
Zacks Investment Research on MSN
Vertex (VRTX) Is Considered a Good Investment by Brokers: Is That True?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...
Vertex Pharmaceuticals (VRTX) announced that the FDA has granted breakthrough therapy designation to povetacicept for the treatment of IgAN. Pove ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback